Flag of the European Union EU Clinical Trials Register Help

Clinical trials for liquid placebo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    208 result(s) found for: liquid placebo. Displaying page 1 of 11.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-000678-44 Sponsor Protocol Number: GA1116 Start Date*: 2012-09-04
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Ltd
    Full Title: A single-centre, randomised, four-way crossover study to investigate the measurement of the acid pocket and subsequent gastro-oesophageal reflux episodes using a novel pH/impedance catheter in subj...
    Medical condition: A single-centre, randomised, four-way crossover study to investigate the measurement of the acid pocket and subsequent gastro-oesophageal reflux episodes using a novel pH/impedance catheter in subj...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001481-16 Sponsor Protocol Number: 113518 Start Date*: 2015-05-13
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase I, double-blind, randomised, placebo-controlled study to assess the reactogenicity and safety of two doses of GlaxoSmithKline Biologicals’ (GSK) oral live attenuated liquid human rotavirus ...
    Medical condition: Healthy volunteers (Active immunisation of infants against gastroenteritis (GE) due to rotavirus (RV))
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-001544-11 Sponsor Protocol Number: 109216 Start Date*: 2015-06-09
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, randomized, double-blind, placebo-controlled study to evaluate the immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated huma...
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-000539-42 Sponsor Protocol Number: RB2-NL-1518 Start Date*: 2016-04-15
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Limited
    Full Title: A randomised, single dose, crossover, open label, placebo controlled confirmatory study in healthy volunteers to characterise the acid neutralisation activity of Gaviscon Double Action Liquid in th...
    Medical condition: To investigate the pH of the acid in the stomach of healthy volunteers after the intakeof Gaviscon Double Action liquid.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-003174-17 Sponsor Protocol Number: GA1405 Start Date*: 2015-03-24
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Limited
    Full Title: A multicentre, randomised, double-blind, two arm, parallel group, placebo controlled pivotal study to assess the effect of a sodium alginate liquid suspension as add-on therapy in GORD patients wit...
    Medical condition: Gastro-Oesophageal Reflux Disease (GORD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-003590-41 Sponsor Protocol Number: EA-14-01-077 Start Date*: 2014-12-15
    Sponsor Name:Engelhard Arzneimittel GmbH & Co.KG
    Full Title: Randomized, controlled, double-blind, multi-center trial to evaluate the efficacy and safety of a liquid containing ivy leaves dry extract vs. placebo in the treatment of acute cough
    Medical condition: Acute cough
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004855 10066522 Acute cough LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003158-15 Sponsor Protocol Number: GA1406 Start Date*: 2014-10-10
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Limited
    Full Title: A randomised, assessor blind, placebo controlled exploratory study in healthy volunteers, to characterise the acid neutralisation activity of sodium alginate oral suspension in the fasted state, us...
    Medical condition: To pilot the use of a custom designed pH catheter for the measurement of intragastric pH to characterise the antacid action of Gaviscon Double Action versus placebo.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-002426-37 Sponsor Protocol Number: EA-16-01-077 Start Date*: 2016-09-27
    Sponsor Name:Engelhard Arzneimittel GmbH & Co.KG
    Full Title: Randomized, placebo-controlled, double-blind, multi-center trial to evaluate the efficacy and safety of 2 Prospan® posologies (2x 7.5 mL/day and 3x 5 mL/day) in the treatment of acute bronchitis
    Medical condition: Acute bronchitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10000687 Acute bronchitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005200-18 Sponsor Protocol Number: 113808 Start Date*: 2015-05-13
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, double-blind, randomised, placebo-controlled, multi-centre study to assess the efficacy, immunogenicity and safety of two doses of GSK Biologicals’ oral live attenuated liquid human ro...
    Medical condition: Healthy volunteers (Active immunisation of infants against gastroenteritis (GE) due to rotavirus (RV))
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-000617-23 Sponsor Protocol Number: SHP647-307 Start Date*: Information not available in EudraCT
    Sponsor Name:Shire Human Genetic Therapies, Inc.
    Full Title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn’s Disease (CARMEN CD 307)
    Medical condition: Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10011402 Crohn's disease (colon) LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) AT (Completed) LT (Completed) CZ (Prematurely Ended) BE (Completed) ES (Prematurely Ended) HU (Completed) SK (Completed) DE (Completed) PT (Completed) EE (Completed) PL (Completed) BG (Completed) GR (Completed) HR (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2015-001547-37 Sponsor Protocol Number: 113552 Start Date*: 2015-06-11
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase I, double-blind, randomised, placebo controlled study to evaluate the reactogenicity and safety of a single oral dose of GlaxoSmithKline (GSK) Biologicals’ live attenuated liquid human rota...
    Medical condition: Rotavirus gastroenteritis
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-021630-63 Sponsor Protocol Number: GA1001 Start Date*: 2011-03-28
    Sponsor Name:Reckitt Benckiser
    Full Title: A randomised, double blind placebo controlled study in patients with reflux symptoms to assess suppression of gastro-oesophageal reflux by ‘Gaviscon Double Action Peppermint liquid’ using the BRAVO...
    Medical condition: Gastro-oesophageal reflux disease (GORD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-004131-23 Sponsor Protocol Number: GA1212 Start Date*: 2013-01-18
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Ltd
    Full Title: A single-centre, randomised, 2 way crossover, double blind, placebo controlled study in healthy volunteers, to characterise the antacid activity of Gaviscon Double Action Mint Liquid in the fasted ...
    Medical condition: This study is to demonstrate the antacid action of Gaviscon Double Action Mint versus a matched placebo using a pH catheter.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000575-88 Sponsor Protocol Number: SHP647-305 Start Date*: 2019-02-28
    Sponsor Name:Shire Human Genetic Therapies, Inc.
    Full Title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn’s Disease (CARMEN CD 305)
    Medical condition: Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) AT (Completed) LT (Completed) CZ (Prematurely Ended) DE (Completed) PL (Completed) HR (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2015-002478-19 Sponsor Protocol Number: SHP616-300 Start Date*: 2016-06-28
    Sponsor Name:Shire ViroPharma, Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Two-period, Three-sequence, Partial Crossover Study to Evaluate the Efficacy and Safety of Subcutaneous Administration of 2000 IU of C1 Este...
    Medical condition: hereditary angioedema
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10019860 Hereditary angioedema PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-004725-27 Sponsor Protocol Number: GA1109 Start Date*: 2012-01-24
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Ltd
    Full Title: A single-centre, randomised, double-blind, two-way crossover, placebo-controlled pilot study, investigating the use of a novel intragastric and oesophageal pH catheter to characterise the antacid a...
    Medical condition: To pilot the use of a novel pH catheter for the measurement of oesophageal and intragastric pH comparing the onset and duration of antacid action of Gaviscon Double Action versus placebo.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-005694-31 Sponsor Protocol Number: 2012/ADE002 Start Date*: 2013-07-05
    Sponsor Name:Adenovir Pharma AB
    Full Title: Evaluation of the Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Acute Phase Adenoviral-Induced Epidemic Keratoconjunctivitis (EKC). A Randomised, Double-Masked, Placebo-Controlled, Mult...
    Medical condition: Acute phase Adenoviral-induced Epidemic Keratoconjunctivitis, EKC
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10014975 Epidemic keratoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-000576-29 Sponsor Protocol Number: SHP647-306 Start Date*: Information not available in EudraCT
    Sponsor Name:Shire Human Genetic Therapies, Inc.
    Full Title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn’s Disease (CARMEN CD 306)
    Medical condition: Crohn’s disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10011402 Crohn's disease (colon) LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) BE (Completed) HU (Completed) SK (Completed) ES (Prematurely Ended) PT (Completed) EE (Completed) BG (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2017-004420-30 Sponsor Protocol Number: CL3-95008-002 Start Date*: 2018-10-04
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Efficacy and safety of bumetanide oral liquid formulation in children aged from 2 to less than 7 years old with Autism Spectrum Disorder. A 6-month randomised, double-blind, placebo controlled mult...
    Medical condition: Autism Spectrum Disorder (ASD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10063844 Autism spectrum disorder PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) ES (Prematurely Ended) NL (Not Authorised) HU (Completed) PT (Completed) PL (Prematurely Ended) IE (Prematurely Ended) CZ (Completed) SK (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006704-10 Sponsor Protocol Number: MICUMA Start Date*: 2007-03-16
    Sponsor Name:JADO Technologies GmbH
    Full Title: Efficacy and Safety of Miltefosine in Cutaneous Mastocytosis
    Medical condition: chronic stable symptomatic maculopapulous cutaneous mastocytosis or systemic mastocytosis with involvement of the skin and with positive Darier´s sign
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012812 Diffuse cutaneous mastocytosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 04 17:15:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA